Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Imaging correlates of the blood–brain barrier disruption in HIV-associated neurocognitive disorder and therapeutic implications

Chaganti, Jogaa; Marripudi, Karthika; Staub, Lukas P.b; Rae, Caroline D.c; Gates, Thomas M.d; Moffat, Kirsten J.a; Brew, Bruce J.a,d

doi: 10.1097/QAD.0000000000002300
CLINICAL SCIENCE
Buy

Objective: HIV-associated neurocognitive disorders (HANDs) in the context of suppressive combination antiretroviral therapy (cART) still occur. We explored the role of blood–brain barrier (BBB) disruption in the pathogenesis of HAND in the context of fully suppressive cART using dynamic contrast enhanced perfusion (DCE-P) MRI. DCE-P is a new MRI technique that measures capillary permeability as an indicator for BBB integrity. We hypothesized that virally suppressed incident HAND would be associated with an impaired BBB as determined by DCE-P.

Design: A cross sectional study.

Methods: K-trans, a metric derivative of DCE-P, was obtained from different regions of the brain in a cohort of 20 patients with HAND who were virally suppressed in both cerebrospinal fluid (CSF) and blood compared with CSF and blood markers of neuroinflammation as well as with neurometabolites derived from magnetic resonance (MR) spectroscopy.

Results: The K-trans data showed significantly impaired BBB in HAND patients when compared with the controls in the regions of the basal ganglia and anterior frontal white matter (both P < 0.0001). CSF neopterin and CSF/serum albumin ratio correlated positively with K-trans but not with blood levels.

Conclusion: This study indicates that HAND in the context of viral suppression is associated with BBB disruption and the DCE MR derived K-trans metric is a very sensitive parameter to identify the BBB disruption. The finding of region-specific BBB disruption rather than globally and the lack of correlation with blood markers of neuroinflammation suggest that HIV and not systemic inflammation is driving the BBB disturbance and that the BBB disruption is a consequence of HIV already in the brain as opposed to HIV first causing BBB disruption then brain disease.

aSt Vincent's Hospital

bNHMRC Clinical trials centre, University of Sydney

cNeuroscience Research Australia

dDepartment of Medicine (Neurology), University of New South Wales, Neurosciences Program and Peter Duncan Neurosciences Unit, St Vincent's Centre for Applied Medical Research, Departments of Neurology and Immunology, St Vincent's Hospital Victoria St, Sydney, New South Wales, Australia.

Correspondence to Joga Chaganti, St Vincent's Hospital, Victoria Street, Darlinghurst, Sydney, NSW 2100, Australia. Tel: +61 2 83823495; e-mail: joga.chaganti@svha.org.au

Received 25 December, 2018

Revised 20 May, 2019

Accepted 26 May, 2019

Copyright © 2019 Wolters Kluwer Health, Inc.